Investing.com - NGM Biopharma (NASDAQ: NGM) reported first quarter EPS of $-0.33, $0.06 better than the analyst estimate of $-0.39. Revenue for the quarter came in at $165K versus the consensus estimate of $558.2K.
NGM Biopharma's stock price closed at $1.54. It is up 93.91% in the last 3 months and down -60.31% in the last 12 months.
NGM Biopharma saw 2 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See NGM Biopharma's stock price’s past reactions to earnings here.
According to InvestingPro, NGM Biopharma's Financial Health score is "weak performance".
Check out NGM Biopharma's recent earnings performance, and NGM Biopharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar